Technipro Pulmomed

Our vision is shared with that of PARI GmBH, that is, to improve the lives of those affected by respiatory diseases, specifically Cystic Fibrosis, and those who care for them. Our focus is marketing a portfolio of world renowned products for comprehensive management of cystic fibrosis, bronchiectasis & other chronic respiratory diseases. Our product range includes a range of leading world renowned products including the innovative Pari® aerosol medication delivery products, pharmaceuticals for cystic fibrosis such as Panzytrat® (pancreatic enzymes), MucoClear® Hypertonic Saline, VitABDECK multivamins, and PMD Spiro PD Personal Spirometers.
Social Link - Linkedin: http://www. linkedin.com/company /pulmomed-australia-pty-ltd
Employee Count: 1
Keywords: hospital & health care

Technipro Marketing was founded in 1984 to identify, develop and market high quality specialised products for under-served medical markets.

Technipro's traditional focus has been in niche areas of respiratory medicine, especially comprehensive disease management for cystic fibrosis, respiratory function monitoring and gas exchange /analysis.

In July 2010, Technipro was proud to announce that it divided its business operations into two companies comprising of Technipro-PulmoMed Pty Ltd (ABN 54 002 730 421) and it’s subsidiary, SMR-Tech Pty Ltd (ABN 12 103 215 603). The subdivision is due to the expansion of our business activities which now include product lines beyond the traditional Technipro cystic fibrosis activities.

Our focus is marketing a portfolio of world renowned products for comprehensive management of cystic fibrosis, bronchiectasis & chronic respiratory diseases.